Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5447)	1/16/2002 10:53:08 AM
From: Extra Pale	Respond to of 52153

Thanks Peter for the provocative read. Seems that the intangible costs of suffering and loss of productivity, absorbed by the patient and community, are omitted from the hospital calculation. No doubt the 68 patients and their families that suffer complications (or deaths) that could have been prevented for the cost of a few hundred $'s would like to re-work the economic calculations.

To: Biomaven who wrote (5447)	1/16/2002 10:57:57 AM
From: Harold Engstrom	Respond to of 52153

"But Meanwell and others at the Medicines Co. believed that if they could lower the manufacturing costs, the rest of the economic picture would fall into place. That would allow them to charge less for the drug, which, combined with the reduction in costly complications, could make the drug competitive." Have never heard that manufacturing costs were the key to profitability in selling proprietary pharmaceuticals. Gross margins are usually 80%-90%. An enormous amount of money has been spent in developing and testing Angiomax, but manufacturing costs should be relatively low. Angiomax could have many applications: its half-life is not terrifically short like that of heparin; it can bind to surfaces as well and be used to coat wetted-surfaces. H